Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-03-08 Director's Dealing
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA – Mandatory trade notification and disclosure of holding
Director's Dealing Classification · 100% confidence The document text is titled "NOTIFICATION OF TRANSACTION CARRIED OUT BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND RELATED PARTIES". This type of filing specifically reports on personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). The content details sales of shares by entities closely associated with a board member (Leiv Askvig) of Ultimovacs ASA on a specific date (7 March 2024).
2024-03-08 English
Ultimovacs ASA – Mandatory trade notification and disclosure of holding
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Mandatory trade notification and disclosure of holding' concerning transactions by related parties (CGS Holding AS, Helene Sundt AS, and Sundt AS). It references compliance with the Market Abuse Regulation article 19 and Norwegian Securities Trading Act sections related to insider trading/major holdings. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by executives and related parties, even if the transaction is by a major shareholder group rather than a director explicitly named in the text, as the context is insider/related party trading disclosure. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific regulatory disclosure about share ownership changes by insiders/related parties.
2024-03-08 English
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Director's Dealing Classification · 100% confidence The document is a formal filing ('KRT-1500 Skjema') submitted to the 'FINANSTILSYNET THE FINANCIAL SUPERVISORY AUTHORITY OF NORWAY'. The content explicitly details a 'Transaksjonstype' (Transaction type) of 'Salg' (Sale) involving shares ('Aksje') by a 'Nærstående foretak' (Related entity) of a person with management responsibility ('primærinnsider'). This structure—reporting personal share transactions by directors/executives and related parties—directly matches the definition for Director's Dealing reports.
2024-03-07 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Director's Dealing Classification · 99% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar («primærinnsidere») og deres nærstående' (KRT-1500 Form for reporting transactions carried out by persons discharging managerial responsibilities ('insiders') and their connected persons). This structure, detailing transactions by directors/insiders (Stilling / Rolle: Board Member) involving the company's shares (Instrument: Aksje), is characteristic of insider trading reports. Reviewing the definitions, the category 'Director's Dealing (Code: DIRS)' specifically covers 'Report of personal share transactions by company directors and executives (insider trades)'. The content perfectly matches this description, detailing a 'Salg' (Sale) transaction by a 'Primærinnsider' (Primary Insider) on 07.03.2024.
2024-03-07 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insiders
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insiders' and details share sales by parties closely related to board members (primary insiders). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for this is DIRS.
2024-03-07 English
Ultimovacs ASA – Disclosure of shareholding
Director's Dealing Classification · 98% confidence The document explicitly states 'Disclosure of shareholding' and details a transaction where 'Watrium AS has today sold 1,780,575 shares in Ultimovacs ASA'. This directly relates to reporting personal share transactions by a significant shareholder or executive, which aligns with the definition of Director's Dealing (DIRS), even though the seller is an entity associated with a major shareholder rather than a director explicitly named. However, given the context of insider/significant shareholder transaction reporting, DIRS is the closest fit among the provided options, as it covers insider trades. If the transaction involved a director, it would definitively be DIRS. Since it involves a major shareholder's transaction disclosure, DIRS is the most appropriate classification for insider/significant transaction reporting.
2024-03-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.